Paul Hartmann
Market Cap
€1.5b
Last Updated
2021/01/22 01:16 UTC
Data Sources
Company Financials
Executive Summary
Paul Hartmann AG manufactures and sells medical and care products in Europe, Africa, Asia, and Oceania. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet, undervalued and pays a dividend.
Similar Companies
Share Price & News
How has Paul Hartmann's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PHH2 is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: PHH2's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
2.0%
PHH2
2.2%
DE Medical Equipment
0.4%
DE Market
1 Year Return
44.4%
PHH2
17.6%
DE Medical Equipment
4.9%
DE Market
Return vs Industry: PHH2 exceeded the German Medical Equipment industry which returned 16.9% over the past year.
Return vs Market: PHH2 exceeded the German Market which returned 3.6% over the past year.
Shareholder returns
| PHH2 | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.0% | 2.2% | 0.4% |
| 30 Day | 14.5% | 6.1% | 4.8% |
| 90 Day | 19.9% | 11.6% | 12.2% |
| 1 Year | 47.6%44.4% | 19.2%17.6% | 8.2%4.9% |
| 3 Year | 12.7%5.7% | 181.9%175.3% | 6.5%-2.8% |
| 5 Year | 3.7%-5.7% | 292.6%276.3% | 45.0%24.7% |
Long-Term Price Volatility Vs. Market
How volatile is Paul Hartmann's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
We're Watching These Trends At Paul Hartmann (FRA:PHH2)1 month ago | Simply Wall St
How Does Paul Hartmann AG (FRA:PHH2) Fare As A Dividend Stock?1 month ago | Simply Wall St
If You Had Bought Paul Hartmann's (FRA:PHH2) Shares Three Years Ago You Would Be Down 16%Valuation
Is Paul Hartmann undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PHH2 (€410) is trading below our estimate of fair value (€968.45)
Significantly Below Fair Value: PHH2 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PHH2 is good value based on its PE Ratio (15.8x) compared to the DE Medical Equipment industry average (48.9x).
PE vs Market: PHH2 is good value based on its PE Ratio (15.8x) compared to the German market (24.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PHH2's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PHH2 is good value based on its PB Ratio (1.6x) compared to the DE Medical Equipment industry average (7.7x).
Next Steps
Future Growth
How is Paul Hartmann forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
13.6%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Paul Hartmann has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine whether Paul Hartmann is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Paul Hartmann competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Paul Hartmann performed over the past 5 years?
-1.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHH2 has high quality earnings.
Growing Profit Margin: PHH2's current net profit margins (3.9%) are higher than last year (3.4%).
Past Earnings Growth Analysis
Earnings Trend: PHH2's earnings have declined by 1.6% per year over the past 5 years.
Accelerating Growth: PHH2's earnings growth over the past year (25.1%) exceeds its 5-year average (-1.6% per year).
Earnings vs Industry: PHH2 earnings growth over the past year (25.1%) exceeded the Medical Equipment industry 7.9%.
Return on Equity
High ROE: PHH2's Return on Equity (10.1%) is considered low.
Next Steps
Financial Health
How is Paul Hartmann's financial position?
Financial Position Analysis
Short Term Liabilities: PHH2's short term assets (€942.9M) exceed its short term liabilities (€456.1M).
Long Term Liabilities: PHH2's short term assets (€942.9M) exceed its long term liabilities (€281.3M).
Debt to Equity History and Analysis
Debt Level: PHH2's debt to equity ratio (2.8%) is considered satisfactory.
Reducing Debt: PHH2's debt to equity ratio has reduced from 13% to 2.8% over the past 5 years.
Debt Coverage: PHH2's debt is well covered by operating cash flow (773.2%).
Interest Coverage: PHH2's interest payments on its debt are well covered by EBIT (51.4x coverage).
Balance Sheet
Next Steps
Dividend
What is Paul Hartmann current dividend yield, its reliability and sustainability?
1.71%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PHH2's dividend (1.71%) is higher than the bottom 25% of dividend payers in the German market (0.97%).
High Dividend: PHH2's dividend (1.71%) is low compared to the top 25% of dividend payers in the German market (3.5%).
Stability and Growth of Payments
Stable Dividend: PHH2's dividends per share have been stable in the past 10 years.
Growing Dividend: PHH2's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (27%), PHH2's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.3yrs
Average management tenure
CEO
Britta Fuenfstueck
2yrs
Tenure
Ms. Britta Fuenfstueck has been Chief Executive Officer at Paul Hartmann AG since January 1, 2019 and its Management Board since January 1, 2019 and has been its Labour Relations Director since January 1, ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairwoman of Management Board | 2yrs | no data | no data | |
| Member of the Management Board & CFO | 0.50yr | no data | no data | |
| Member of Management Board | 12.25yrs | no data | no data | |
| Member of the Management Board | 5.25yrs | no data | no data | |
| Member of the Management Board | 1yr | no data | no data | |
| Vice President of Corporate Legal | no data | no data | no data | |
| Vice President of Human Resources Management | 10yrs | no data | no data | |
| Senior Vice President of Corporate Accounting | no data | no data | no data | |
| Head of Group Purchasing Management | 13yrs | no data | no data | |
| Executive Managing Director of SANIMED Group Germany | 7.33yrs | no data | no data | |
| Senior Vice President Business Unit Risk Prevention | no data | no data | no data | |
| Managing Director of Spain | 24yrs | no data | no data |
7.3yrs
Average Tenure
Experienced Management: PHH2's management team is seasoned and experienced (7.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice President Operations Management Medical Production & Member of Supervisory Board | 3yrs | no data | no data | |
| Member of Supervisory Board | 12.75yrs | €22.50k | no data | |
| Chairman of Supervisory Board | 15.5yrs | €69.50k | no data | |
| Member of Supervisory Board | 12.75yrs | €53.83k | no data | |
| Member of Supervisory Board | 12.75yrs | €22.50k | no data | |
| Member of Supervisory Board | no data | €22.50k | no data | |
| Deputy Chairman of the Supervisory Board | no data | no data | no data | |
| Member of Supervisory Board | 7.67yrs | no data | no data | |
| Member of Supervisory Board | no data | no data | no data | |
| Member of Supervisory Board | no data | no data | no data | |
| Member of Supervisory Board | no data | no data | no data | |
| Member of Supervisory Board | 3yrs | no data | no data |
12.8yrs
Average Tenure
Experienced Board: PHH2's board of directors are seasoned and experienced ( 12.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Paul Hartmann AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Paul Hartmann AG
- Ticker: PHH2
- Exchange: DB
- Founded: 1818
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: €1.456b
- Shares outstanding: 3.55m
- Website: https://hartmann.info
Number of Employees
Location
- Paul Hartmann AG
- Paul-Hartmann-Straße 12
- Heidenheim
- Baden-Württemberg
- 89522
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PHH2 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jan 1992 |
| PLHN.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Jan 1992 |
Biography
Paul Hartmann AG manufactures and sells medical and care products in Europe, Africa, Asia, and Oceania. It offers disinfectant products for hands, surface, and instruments; cleaning, skin care, and skin an...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/22 01:16 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.